Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.01 is 3486% above its 3-year average of 0.00, near the high end of its 3-year range (-1.98–0.01).
As of the fiscal period ended Tuesday, June 30, 2026. 148.90% above its 12-month average of 0.00.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
DEBT TO EQUITY RATIO
0.01
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+148.90%
CURRENT VS 3Y AVG
+3159.76%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-92.93%
vs the sector median at left
BridgeBio Oncology Therapeutics Inc.
Market Cap
$280.37M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
N/A
Market Cap
$281.54M
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.04
5Y Avg
0.03
Market Cap
$282.64M
Debt to Equity Ratio
0.05
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.50
Market Cap
$284.31M
Debt to Equity Ratio
0.04
TTM Avg
0.11
3Y Avg
0.22
5Y Avg
0.26
Market Cap
$285.42M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$285.55M
Debt to Equity Ratio
0.16
TTM Avg
0.34
3Y Avg
0.33
5Y Avg
0.27
Market Cap
$288.79M
Debt to Equity Ratio
0.04
TTM Avg
0.04
3Y Avg
0.05
5Y Avg
0.06
Market Cap
$271.81M
Debt to Equity Ratio
0.10
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$270.80M
Debt to Equity Ratio
0.07
TTM Avg
0.07
3Y Avg
0.06
5Y Avg
0.07
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $280.37M | 0.01 | 0.00 | 0.00 | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | 0.02 | 0.03 | 0.04 | 0.03 |
| Standard BioTools Inc. (LAB)vs › | $282.64M | 0.05 | 0.07 | 0.07 | 0.50 |
| Aurora Cannabis Inc. (ACB)vs › | $284.31M | 0.04 | 0.11 | 0.22 | 0.26 |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.42M | 0.01 | 0.00 | 0.00 | 0.00 |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | 0.16 | 0.34 | 0.33 | 0.27 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $288.79M | 0.04 | 0.04 | 0.05 | 0.06 |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | 0.10 | 0.03 | 0.03 | 0.03 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | 0.07 | 0.07 | 0.06 | 0.07 |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | 0.05 | N/A | N/A | N/A |
Debt/Equity
0.01
Current Ratio
4.69
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.01 |
| 2026-03-31 | 0.01 |
| 2025-12-31 | 0.01 |
| 2025-09-30 | 0.01 |
| 2025-06-30 | -0.01 |
| 2025-03-31 | -0.01 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | -1.10 |
| 2023-09-30 | -1.98 |
| 2022-12-31 | 0.00 |
